Showing results (361-370 of 1,343) with videos related to
Sort By:
Pageof 135
Revue Medicale Suisse|September 16, 2006
[Drug therapy in the elderly. What should we know?]P Wotquenne, J Petermans, A J ScheenDiabetes & Metabolism|April 7, 2007
Abnormal glucose metabolism in patients treated with antipsychoticsA J Scheen, M A De HertRevue Medicale De Liege|August 17, 2006
[Do statins have a place for cardiovascular prevention in elderly people?]J Petermans, J Laperche, A J ScheenRevue Medicale De Liege|August 20, 2015
[STRENGTHS AND WEAKNESSES OF RANDOMISED CLINICAL TRIALS: EVOLVING CHANGES ACCORDING TO PERSONALIZED MEDICINE]Ph Ernest, B Jandrain, A J ScheenRevue Medicale De Liege|December 5, 2008
[Benefit-risk ratio of coronary drug-eluting stents. 1st part: evaluation in the global population]A Nyssen, V Legrand, A J ScheenRevue Medicale Suisse|October 7, 2011
[Type 2 diabetes and anti-inflammatory agents: new therapeutic prospects?]N Esser, N Paquot, A J ScheenRevue Medicale De Liege|October 5, 2001
[Finapres, efficient technique in the assessment of orthostatic hypotension, autonomic neuropathy, and vaso-vagal syncope]A J Scheen, I Geronooz, M MarchandRevue Medicale De Liege|July 23, 2005
[Type 2 diabetes, in the heart of the metabolic syndrome: plea for a global approach]A J Scheen, L F Van GaalRevue Medicale De Liege|January 26, 2013
[How I explore ... a risk difference in the occurrence of an event in clinical trials]A J Scheen, P Ernest, B JandrainRevue Medicale De Liege|December 9, 2022
[Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy]A J Scheen, C Wallemacq, P LancellottiPageof 135